Accuray (NASDAQ:ARAY) Stock Rating Upgraded by Wall Street Zen

Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings cut Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 1st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

View Our Latest Report on Accuray

Accuray Price Performance

Shares of ARAY opened at $2.80 on Friday. The company has a current ratio of 1.56, a quick ratio of 0.71 and a debt-to-equity ratio of 1.79. Accuray has a 12 month low of $2.75 and a 12 month high of $45.20. The firm’s 50 day moving average is $7.70 and its 200-day moving average is $13.46. The stock has a market capitalization of $8.37 million, a PE ratio of -0.47 and a beta of 1.38.

Accuray (NASDAQ:ARAY – Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.40. The business had revenue of $100.92 million during the quarter, compared to analysts’ expectations of $105.30 million. Accuray had a negative return on equity of 35.36% and a negative net margin of 4.41%.

Hedge Funds Weigh In On Accuray

Several hedge funds have recently bought and sold shares of ARAY. Kovack Advisors Inc. lifted its holdings in shares of Accuray by 7.1% during the 3rd quarter. Kovack Advisors Inc. now owns 1,125,979 shares of the medical equipment provider’s stock worth $301,000 after acquiring an additional 75,083 shares during the period. Williams & Novak Wealth Management LLC boosted its position in shares of Accuray by 27.3% during the 3rd quarter. Williams & Novak Wealth Management LLC now owns 303,330 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 65,100 shares in the last quarter. Squarepoint Ops LLC increased its stake in Accuray by 164.7% in the second quarter. Squarepoint Ops LLC now owns 1,448,234 shares of the medical equipment provider’s stock valued at $373,000 after acquiring an additional 901,158 shares during the last quarter. Susquehanna International Group LLP increased its stake in Accuray by 2,344.3% in the second quarter. Susquehanna International Group LLP now owns 825,604 shares of the medical equipment provider’s stock valued at $213,000 after acquiring an additional 791,827 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in Accuray in the second quarter valued at approximately $28,000. 64.08% of the stock is owned by institutional investors.

About Accuray

(Get Free Report)

Accuray Incorporated develops, manufactures, and sells radiation therapy systems and related software for treating cancer and other conditions. Its technologies are used by hospitals and cancer treatment centers to plan and deliver radiation treatments. The company’s products include the CyberKnife platform, a robotic system designed to deliver stereotactic radiosurgery and radiation therapy, and the Radixact platform, which uses helical tomotherapy to deliver image-guided radiation treatments. Accuray also provides treatment-planning software, service, and support for its systems.

Further Reading

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.